The Antiphospholipid Antibody Syndrome

• REFERENCES

• 1 Italian Registry of Antiphospholipid Antibodies (IR-APA).. Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italien Registry. Haematolog-ica 1993; 78: 313-8.
• 2 Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508-12.
• 3 Asherson RA. Anti-phospholipid antibodies: clinical complications reported in medical literature. In: Phospholipid-binding antibodies. Harris EN, Exner T, Hughes GRV, Asherson RA. (eds) Boca Raton: CRC Press; 1991: 387-402.
• 4 Asherson RA, Khamashta MA, Ordi-Ros J. et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-74.
• 5 Alarcon-Segovia D, Deleze M, Oria CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a review of 500 consecutive cases. Medicine 1989; 68: 353-65.
• 6 Loizou S, McCrea JD, Rudge AC. et al. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol 1985; 62: 739-44.
• 7 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: an update. Thromb Haemostas 1995; 74: 1185-90.
• 8 Lechner K, Pabinger-Fasching I. Lupus anticoagulant and thrombosis. Hemostasis 1985; 15: 254-62.
• 9 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci (USA) 1990; 87: 4120-4.
• 10 Galli M, Comfurius P, Maassen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofac-tor. Lancet 1990; 334: 1544-7.
• 11 Matsuura E, Igarashi Y, Fujimoto M. et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet (Letter) 1990; 335: 177-8.
• 12 Bevers EM, Galli M. β₂-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Lancet (Letter) 1990; 335: 952-3.
• 13 Galli M, Comfurius P, Barbui T. et al. Anticoagulant activity of β₂-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemostas 1992; 68: 297-300.
• 14 Galli M, Bevers EM, Comfurius P. et al. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Brit J Haematol 1993; 83: 466-72.
• 15 Matsuura E, Igarashi Y, Yasuda T. et al. Anticardiolipin antibodies recognize β₂-glyco-protein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
• 16 Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β₂-glycoprotein I is bound to a suitable surface. Thromb Haemostas 1995; 73: 29-34.
• 17 Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” antibodies recognize β₂-glycoprotein I in the absence of phospholipid. Importance of antigen density and bivalent binding. J Immunol 1995; 154: 954-60.
• 18 Bevers EM, Galli M, Barbui T. et al. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of li-pid-bound human prothrombin. Thromb Haemostas 1991; 66: 629-32.
• 19 Rao VM, Hoang AD, Rapaport SI. Differences in the interactions of lupus anticoagulant IgG with human and govine prothrombin. Thromb Haemostas 1995; 73: 668-74.
• 20 Arvieux J, Darnige L, Reber G. et al. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemostas 1995; 74: 1120-5.
• 21 Oosting JD, Derksen RHWM, Bobbink IWG. et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenetic mechanisms. Blood 1993; 81: 2618-25.
• 22 Matsuda J, Saitoh N, Gohci K. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or an-ticardiolipin antibody. Am J Hematol 1994; 47: 56-8.
• 23 Gibson J, Nelson M, Brown R. et al. Autoantibodies to thrombomodulin: development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemostas 1992; 67: 507-9.
• 24 Sugi T, Mcintyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-9.
• 25 Kandiah DA, Krilis SA. Beta 2-glycoprotein I. Lupus 1994; 3: 207-12.
• 26 Schousboe I. Beta 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
• 27 Nimpf J, Bevers EM, Bomans PH. et al. Pro-thrombinase activity of human platelets is inhibited by beta 2-glycoprotein I. Biochim Biophys Acta 1986; 884: 142-9.
• 28 Nimpf J, Wurm H, Kostner GM. Beta 2-glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109-14.
• 29 Bancsi LFJMM, van der Linden IK, Bertina RM. β₂-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemostas 1992; 67: 649-53.
• 30 Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and β₂-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-92.
• 31 Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of LA antibodies in patients with antiphospholipid antibodies. (submitted).
• 32 Puri RN, Zhou F, Hu CJ, Colman RW. High molecular weight kininogens inhibits throm-bin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 1991; 77: 500-7.
• 33 Berard M, Sugi T, Mcintyre JA. et al. Prevalence and kininogen-dependence of anti phosphatidylethanolamine antibodies. Nouv Rev franc Hematol 1995; 37 (Suppl. 02) S69-S72.
• 34 Smirnov MD, Triplett DA, Comp PC. et al. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
• 35 Smeets EF, Comfurius P, Bevers EM, Zwaal RFA. Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res (in press).
• 36 Branch DW, Dudley DJ, Mitchell MD. et al. IgG fraction from patients with antiphospholipid antibodies cause fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 120.
• 37 Gharavi AE. Anti-phospholipid syndrome in murine lupus. In: phospholipid-binding antibodies. Harris EN, Exner T, Asherson RA, Hughes GRV. (eds) Boca Raton, Florida: CRC Press; 1991: 403-16.
• 38 Blank M, Cohen J, Toder C. et al. Induction of APS in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci (USA) 1991; 88: 3069-73.
• 39 Bakimer R, Fishman E, Blank M. et al. Induction of primary APS in mice by immunization with a human monoclonal anticar-diolipin antibody (H-3). J Clin Invest 1992; 89: 1558-63.
• 40 Hashimoto Y, Kawamura M, Ichikawa K. et al. Anticardiolipin antibodies in NZW व B BXSB Fl mice: a model of antiphospholipid syndrome. J Immunol 1992; 149: 1063-8.
• 41 Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemostas 1994; 71: 670-4.
• 42 Green D, Hougie C, Kazmier FJ. et al. Report of the Working Party on acquired inhibitors of coagulation: studies of the “Lupus Anticoagulant”. Thromb Haemostas 1983; 49: 144-6.
• 43 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemostas 1995; 74: 1185-90.
• 44 Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β₂-glycoprotein I of the factor Xa activity of platelets. Thromb Haemostas 1993; 70: 342-5.
• 45 Ogasawara M, Aoki K, Matsuura E, Kuni-matsu M, Ohkubo I, Galli M, Sasaki M, Ya-gami Y. Anticardiolipin antibodies in patients with pregnancy loss induce factor Xa production in the presence of β₂-Glycopro-tein I. Am J Reproduct Immunol 1995; 34: 269-73.
• 46 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between pro-thrombin-dependent and β₂-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-23.
• 47 Reber G, Arvieux J, Comby E. et al. Multi-center evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemostas 1995; 73: 444-52.
• 48 Falcon CR, Hoffer AM, Forastiero RR, Carreras LO. Clinical significance of various ELISA assays for detecting antiphospholipid antibodies. Thromb Haemostas 1990; 64: 21-5.
• 49 Ginsberg JS, Wells PS, Brill-Edwards P. et al. Antiphospholipid antibodies and venous thromboembolism. Bloos 1995; 86: 3685-91.
• 50 Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-inducecl platelet activation and thromboxane formation. Thromb Haemostas 1993; 70: 667-71.
• 51 Oosting JD, Derksen RHWM, Blokzijl L. et al. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity – Studies in a thrombosis model. Thromb Haemostas 1992; 68: 278-84.
• 52 de Prost V, Ternisien C, Chollet-Martin S. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus. Thromb Haemostas 1990; 64: 216-21.
• 53 Lin Y-L, Wang C-T. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80: 3135-43.
• 54 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32.
• 55 Borrell M, Sala N, de Castellarnau C. et al. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemostas 1992; 68: 268-72.
• 56 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Int Med 1990; 112: 682-98.
• 57 Long AA, Ginsberg JS, Brill-Edwards P. et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemostas 1991; 66: 520-5.
• 58 Ginsberg JS, Wells PS, Brill-Edwards P. et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
• 59 Bongard O, Reber G, Bounameaux H, de Moerloose P. Anticardiolipin in acute venous thromboembolism. Thromb Haemostas 1992; 67: 724.
• 60 The Antiphospholipid Antibodies in Stroke Study Group (APASS).. Clinical, radiological and pathological aspects of cerebrevascu-lar disease associated with antiphospholipid antibodies. Stroke 1993; 24 Suppl I 1-120-1-123.
• 61 Ginsburg KS, Liang MH, Newcomer L. et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
• 62 Vaarala O, Mänttäri M, Manninen V. et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7.
• 63 Finazzi G, Brancaccio V, Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a five-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
• 64 Levine SR, Brey RL, Joseph CML, Havstad S. on behalf of the APASS. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992; 23 (Suppl. 01) 1-29-32.
• 65 Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992; 23: 189-93.
• 66 Hamsten A, Bjorkholm M, Norberg R, de-Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular event. Lancet 1986; i: 113-6.
• 67 Sletnes KE, Smith P, Abedlnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies and myocardial infarction and their relation to mortality, reinfarction and non-haemor-rhagic stroke. Lancet 1992; 339: 451-3.
• 68 Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism and intensity of warfarin anticoagulation. Thromb Haemostas 1996; 75: 859.
• 69 Vianna JL, Khamashta MA. Ordi-Ros et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9.
• 70 Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99: 624-8.
• 71 Barbui T, Finazzi G. Clinical trials on Antiphospholipid Syndrome: what is done and what is needed?. Lupus 1994; 3: 303-8.
• 72 Rosove MH, Brewer PMC. Antiphospholipid antibodies: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8.
• 73 Berksen RHWM, de Groot PG, Kater L. et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-92.
• 74 Khamashta MA, Cuadrado MJ, Mujic F. et al. The management of thrombosis in the antiphospholipid syndrome. New Engl J Med 1995; 332: 993-7.
• 75 Della Valle P, Grippa L, Safa O. et al. Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Second Meeting of the European Haematology association. Workshop on an-tiphospholipid-protein antibodies: Practical aspects. Paris june 1st, 1996.
• 76 Finazzi G, Barbui T. Proposal of a clinical trial of high-dose warfarin in the antiphospholipid syndrome: the WAPS trial. Seventh International Symposium on Antiphospholipid Antibodies. New Orleans, October 9-13, 1996.
• 77 Harris EN, Gharavi EN, Hedge U. et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol 1985; 59: 231-4.
• 78 Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol 1996; 93: 1-5.
• 79 Galli M, Daldossi M, Barbui IT. Anti-glyco-protein Ib/IX and Ilb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemostas 1994; 71: 571-5.
• 80 He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994; 83: 1024-32.
• 81 Fabris F, Steffan A, Cordiano I. et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994; 53: 232-6.
• 82 Stasi R, Stipa E, Oiva F. et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84: 4203-7.
• 83 Cortelazzo S, Finazzi G, Buelli M. et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 31-3.
• 84 Drenkard C, Villa AR, Alarcon-Segovia D, Perez-Vasquez ME. Influence of antiphos-phàolipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 1067-72.
• 85 Stasi R, Stipa E, Masi M. et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-42.
• 86 Hasselaar P, Derksen RHWM, Blokzijl L. et al. Risk factors for thrombosis in lupus patients. Ann Rheum Dis 1989; 48: 933-40.
• 87 Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 175-80.
• 88 Orlando E, Cortelazzo S, Marchetti M. et al. Prolonged bleeding time in patients with lupus anticoagulant. Thromb Haemostas 1992; 68: 495-9.
• 89 Branch DW. Thoughts on the mechanism of pregnancy loss associated with the Antiphospholipid Syndrome. Lupus 1994; 3: 275-80.
• 90 MacLachlan NA, Elder MG. Anti-phospholipid antibodies and fetal loss. Proposed mechanisms. In: Phospholipid-binding antibodies. Harris EN, Exner T, Hughes GRV, Asherson RA. (eds) Boca Raton: CRC Press; 1991: 355-69.
• 91 Branch DW, Dudley DJ, Mitchell MD. et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210-6.
• 92 Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1983; i: 1361-3.
• 93 Cowchock FS, Reece EA, Balaban D. et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318-3.
• 94 Out HJ, Bruinse HW, Christiaensen GCML. et al. A prospective, controlled multicenter study on the obstetric risk of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26-32.
• 95 Cohen H. Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome. Second Meeting of the European Haematology association. Workshop on antiphospholipid-protein antibodies: Practical aspects. Paris june 1st, 1996.
• 96 Fleck R, Rapaport SI, Rao VM. Anti-pro-thrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-9.
• 97 Simel DL, Clair St. EW, Adams J, Green-berg CS. Correction of hypoprothrombin-emia by immunsuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med 1987; 83: 563-6.